Immune to Cancer: The CRI Blog
-
CICON19 Day 1 Update: Cancer Prevention and Combination Immunotherapy Strategies
Day 1 of CICON19 explored how checkpoint immunotherapy might be improved through combination strategies as well as…
-
CICON19 Preview: Translating Science into Survival
Topics at the upcoming CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CICON19) in Paris include prevention, the tumor microenvironment,…
-
CICON18 Day 4 Update: The Role of Bacteria; Technologies to Advance Cancer Immunotherapy
The final day of CICON18 explored two diverse areas—technology and the microbiome—that both have the…
-
CICON18 Day 3 Update: Targeting Tumor Mutations with Vaccine-Based Immunotherapies
The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish…
-
CICON18 Preview: Translating Science into Survival
Highlights from the upcoming International Cancer Immunotherapy Conference (CICON18), including regulating T cell response, tackling the tumor…
-
CICON17 Day 4 Recap: The Tumor Microenvironment and Oncolytic Viruses
The final day of CICON17 explored two newer immunotherapy approaches that reflect broader understanding of tumor-immune interactions…
-
CICON17 Day 3 Recap: Combinations, Checkpoint Immunotherapy Resistance, Immunomodulators, and Microbiota
Day 3 of the CICON17 focused on combination therapies, immunomodulators, overcoming immune suppression, and the role bacteria in…
-
CICON17 Day 2 Recap: Biomarkers, Novel Agents, and Adoptive Cell Therapies
Day 2 of CICON17 offered a focused exploration of the latest discoveries and data from scientific studies…